Endologix Given Consensus Recommendation of “Hold” by Analysts (NASDAQ:ELGX)
Shares of Endologix (NASDAQ:ELGX) have been given a consensus recommendation of “Hold” by the eight brokerages that are presently covering the stock, AnalystRatings.Net reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $17.90.
In other Endologix news, Director Thomas Wilder unloaded 3,500 shares of the company’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $13.68, for a total transaction of $47,880.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of research firms have recently commented on ELGX. Analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Endologix in a research note on Thursday, July 31st. They now have a $17.00 price target on the stock, up previously from $15.00. Separately, analysts at Credit Suisse initiated coverage on shares of Endologix in a research note on Tuesday, July 29th. They set an “outperform” rating on the stock. Finally, analysts at BTIG Research downgraded shares of Endologix from a “buy” rating to a “neutral” rating in a research note on Monday, July 7th.
Endologix (NASDAQ:ELGX) opened at 13.91 on Tuesday. Endologix has a one year low of $11.47 and a one year high of $18.85. The stock’s 50-day moving average is $14.31 and its 200-day moving average is $14.05. The company’s market cap is $931.3 million.
Endologix (NASDAQ:ELGX) last announced its earnings results on Wednesday, July 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.30 million for the quarter, compared to the consensus estimate of $36.50 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 12.6% on a year-over-year basis. On average, analysts predict that Endologix will post $-0.28 earnings per share for the current fiscal year.
Endologix, Inc (NASDAQ:ELGX) is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.